Pfizer Prevnar vaccine wins expanded approval, for ages 6-17
January 25, 2013 at 16:43 PM EST
Jan 25 (Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.